5-(Dimethoxymethyl)-2′-deoxyuridine: A novel gem diether nucleoside with anti-orthopoxvirus activity

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3377-3382

  Fan, Xuesen ^a   Zhang, Xinying ^a   Zhou, Longhu ^a   Keith, Kathy A ^b   Kern, Earl R ^b   Torrence, Paul F ^a  

^a NORTHERN ARIZONA UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [TETRAHYDRO 4 HYDROXY 5 (HYDROXYMETHYL)FURAN 2 YL] 5 (DIETHOXYMETHYL)PYRIMIDINE 2,4(1H,3H) DIONE; 1 [TETRAHYDRO 4 HYDROXY 5 (HYDROXYMETHYL)FURAN 2 YL] 5 (DIMETHOXYMETHYL)PYRIMIDINE 2,4(1H,3H) DIONE; 5 (1,3 DIOXAN 2 YL) 1 [TETRAHYDRO 4 HYDROXY 5 (HYDROXYMETHYL)FURAN 2 YL]PYRIMIDINE 2,4(1H,3H) DIONE; 5 (1,3 DIOXOLAN 2 YL) 1 [TETRAHYDRO 4 HYDROXY 5 (HYDROXYMETHYL)FURAN 2 YL]PYRIMIDINE 2,4(1H,3H) DIONE; 5 (DIMETHOXYMETHYL) 2' DEOXYURIDINE; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DECOMPOSITION; DRUG SCREENING; DRUG STRUCTURE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; ORTHOPOXVIRUS; PH; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VACCINIA VIRUS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; COWPOX VIRUS; DEOXYURIDINE; DRUG STABILITY; ESTERASES; ETHERS; FIBROBLASTS; HUMANS; LIVER; ORTHOPOXVIRUS; SKIN; SWINE; VACCINIA VIRUS; WATER;

EID: 33744793223     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0601710     Document Type: Article

References (73)

1. Alberts, B.; Fineberg, H. V. Harnessing new science is vital for biodefense and global health. Proc. Natl Acad. Sci. U.S.A. 2004, 101, 11177.
2. Alibek, K. Smallpox: a disease and a weapon. Int. J. Infect. Dis. 2004, 8, S3-8.
3. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Hitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management. JAMA, J. Am. Med. Assoc. 2001, 285, 1059-1070.
4. Artenstein, A. W. Biodefense: medicine in the time of bioterrorism. Med. Health R. I. 2003, 86, 201-203.
5. Atlas, R. M.; Reppy, J. Globalizing biosecurity. Biosecur. Bioterror 2005. 3, 51-60.
6. Borio, L.; Frank, D.; Mani, V.; Chiriboga, C.; Pollanen, M.; Ripple, M.; Ali, S.; DiAngelo, C.; Lee, J.; Arden, J.; Titus, J.; Fowler, D.; O'Toole, T.; Masur, H.; Bartlett, J.; Inglesby, T. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA, J. Am. Med. Assoc. 2001, 286, 2554-2559.
7. Borio, L.; Inglesby, T.; Peters, C. J.; Schmaljohn, A. L.; Hughes, J. M.; Jahrling, P. B.; Ksiazek, T.; Johnson, K. M.; Meyerhoff, Á.; O'Toole, T.; Ascher, M. S.; Bartlett, J.; Breman, J. G.; Eitzen, E. M., Jr.; Hamburg, M.; Hauer, J.; Henderson, D. A.; Johnson, R. T.; Kwik, G.; Layton, M.: Lillibridge, S.; Nabel, G. J.; Osterholm, M. T.; Perl, T. M.; Russell, P.; Tonat, K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA, J. Am. Med. Assoc. 2002, 287, 2391-2405.
8. Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57, 53-60.
9. Bray, M.; Buller, M. Looking back at smallpox. Clin. Infect. Dis. 2004, 38, 882-889.
10. Bray, M.; Roy, C. J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 2004, 54, 1-5.
11. Bray, M.: Wright, M. E. Progressive vaccinia. Clin. Infect. Dis. 2003, 36, 766-774.
12. Dennis, D. T.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Friedlander, A. M.; Hauer, J.; Layton, M.; Lillibridge, S. R.; McDade, J. E.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Tonat, K. Tularemia as a biological weapon: medical and public health management. JAMA, J. Am. Med. Assoc. 2001, 285, 2763-2773.
13. Goodrich, A.; Parveen, Z.; Dornburg, R.; Schnell, M. J.; Pomerantz, R. J. Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector design. Mol. Ther. 2004, 9, 557-565.
14. Henderson, D. A. The looming threat of bioterrorism. Science 1999. 283, 1279-1282.
15. Henderson, D. A. Countering the posteradication threat of smallpox and polio. Clin. Infect. Dis. 2002, 34, 79-83.
16. Henderson, D. A.; Inglesby, T. V.; Bartlett, J. G.; Ascher, M. S. Eitzen, E.; Jahrling, P. B.; Hauer, J.; Layton, M.; McDade, J. Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T.; Russell, P. K. Tonat, K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA, J. Am. Med. Assoc. 1999, 281, 2127-2137.
17. Kaiser, J. Biodefense. Report faults smallpox vaccination. Science 2005, 307, 1540.
18. O'Toole, T. The problem of biological weapons: next steps for the nation. Public Health Rep. 2001, 116, 108-1 11.
19. O'Toole, T. Emerging illness and bioterrorism: implications for public health. J. Urban Health 2001, 78, 396-402.
20. O'Toole, T.; Inglesby, T. V. Facing the biological weapons threat. Lancet 2000, 356 , 1128-1129.
21. O'Toole, T.; lnglesby, T. V. Epidemic response scenario: decision making in a time of plague. Public Health Rep. 2001, 116, 92-103.
22. O'Toole, T.; Mair, M.; Inglesby, T. V. Shining light on "Dark Winter". Clin Infect. Dis. 2002, 34, 972-983.
23. Smith, B. T.; Inglesby, T. V.; O'Toole, T. Biodefense R&D: anticipating future threats, establishing a strategic environment. Biosecur. Bioterror 2003, 1, 193-202.
24. Bryant, J. E.; Barrett, A. D. Comparative phylogenies of yellow fever isolates from Peru and Brazil. FEMS Immunol. Med. Microbiol. 2003, 39, 103-118.
25. Cohen, J.; Marshall, E. Bioterrorism. Vaccines for biodefense: a system in distress. Science 2001, 294, 498-501.
26. Couzin, J. Biodefense. U. S. agencies unveil plan for biosecurity peer review. Science 2004, 303, 1595.
27. Davis, C. J. Nuclear blindness: An overview of the biological weapons programs of the former Soviet Union and Iraq. Emerging Infect. Dis. 1999, 5, 509-512.
28. Enserink, M. Infectious diseases. New biodefense splurge creates hotbeds, shatters dreams. Science 2003, 302, 206-207.
29. Enserink, M. Biodefense. Smallpox vaccines: looking beyond the next generation. Science 2004, 304, 809.
30. Giangrego, E. Biodefense: it's more than duct tape. CDS Rev. 2003, 96, 10-16.
31. Gilfillan, L.; Smith, B. T.; Inglesby, T. V.; Kodukula, K.; Schuler, A.; Lister, M.; O'Toole, T. Taking the measure of counter-measures: leaders' views on the nation's capacity to develop biodefense countermeasures. Biosecur. Bioterror 2004, 2, 320-327.
32. Goodman, L. Biodefense cost and consequence. J. Clin. Invest. 2004, 114, 2-3.
33. Bray, M. Viral bioterrorism and antiviral countermeasures. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; pp 17-30.
34. Torrence, P. F. Introduction: pestilence, plague, bioterrorism. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; pp 3-16.
35. Arita, I.; Wickelt, J.; Nakane, M. Eradication of infectious diseases: its concept, then and now. Jpn. J. Infect. Dis. 2004, 57, 1-6.
36. Bhalla, D. K.; Warheit, D. B. Biological agents with potential for misuse: a historical perspective and defensive measures. Toxicol. Appl. Pharmacol. 2004, 199, 71-84.
37. Debord, T. Smallpox and bioterrorism. Med. Mal. Infect. 2004, 34, 6-11.
38. Eichner, M.; Schwehm, M. Smallpox: a vulnerable specter. Epidemiology 2004, 15, 258-260. Discussion 260-251.
39. Guharoy, R.; Panzik, R.; Noviasky, J. A.; Krenzelok, E. P.; Blair, D. C. Smallpox: clinical features, prevention, and management. Ann. Pharmacother. 2004, 38, 440-447.
40. Jacobs, L. M.; Emanuelsen, K.; McKay, C.; Burns, K. Bioterrorism preparedness-Part II. Smallpox vaccination in a hospital setting. Conn. Med. 2004, 68, 27-35.
41. Kaplan, E. H. Preventing second-generation infections in a smallpox bioterror attack. Epidemiology 2004, 15, 264-270.
42. Kuljic-Kapulica, N. Smallpox-in the past or not? Srp. Arh. Celok. Lek. 2004, 132, 272-276.
43. Leissner, K. B.; Holzman, R. S.; McCann, M. E. Bioterrorism and children: unique concerns with infection control and vaccination. Anesthesiol. Clin. North Am. 2004, 22, 563-577.
44. Lupatkin, H.; Lupatkin, J. F.; Rosenberg, A. D. Smallpox in the 21st century. Anesthesiol. Clin. North Am. 2004, 22, 541-561.
45. Mahalingam, S.; Damon, I. K.; Lidbury, B. A. 25 years since the eradication of smallpox: why poxvirus research is still relevant. Trends Immunol. 2004, 25, 636-639.
46. Mayr, A. Taking advantage of the positive side-effects of smallpox vaccination. J. Vet. Med., Ser. B 2004, 51, 199-201.
47. Slifka, M. K.; Hanifin, J. M. Smallpox: the basics. Dermatol. Clin. 2004, 22, 263-274.
48. Spuls, P. I.; Bos, J. D.; Rudikoff, D. Smallpox: what the dermatologist should know. Skinmed 2004, 3, 197-206; quiz 207-198.
49. Tennyson, H. C.; Mair, E. A. Smallpox: what every otolaryngologist should know. Otolaryngol. Head Neck Surg. 2004, 130, 323-333.
50. Thornton, R.; Court, B.; Meara, J.; Murray, V.; Palmer, I.; Scott, R.; Wale, M.; Wright, D. Chemical, biological, radiological and nuclear terrorism: an introduction for occupational physicians. Occup. Med. (London) 2004, 54, 101-109.
51. Bray, M.; Martinez, M.; Kefauver, D.; West, M.; Roy, C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 2002, 54, 129-142.
52. Bray, M.; Martinez, M.; Smee, D. F.; Kefauver, D.; Thompson, E.; Huggins, J. W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181, 10-19.
53. De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 2002, 23, 456-458.
54. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55, 1-13.
55. Neyts, J.; Leyssen, P.; Verbeken, E.; De Clercq, E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 2004, 48, 2267-2273.
56. Quenelle, D. C.; Coffins, D. J.; Kern, E. R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 2003, 47, 3275-3280.
57. Roy, C. J.; Baker, R.; Washburn, K.; Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 2003, 47, 2933-2937.
58. Smee, D. F.; Bailey, K. W.; Sidwell, R. W. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 2003, 49, 126-131.
59. Smee, D. F.; Bailey, K. W.; Wong, M. H.; Wandersee, M. K.; Sidwell, R. W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 2004, 190, 1132-1139.
60. Toro, J. R.; Sanchez, S.; Turiansky, G.; Blauvelt, A. Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. Dermatol. Clin. 2003, 21, 301-309.
61. Aldern, K. A.; Ciesla, S. L.; Winegarden, K. L.; Hosteller, K. Y. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]-cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63, 678-681.
62. Bradbury, J. Orally available cidofovir derivative active against smallpox. Lancet 2002, 359, 1041.
63. Ciesla, S. L.; Trahan, J.; Wan, W. B.; Beadle, J. R.; Aldern, K. A.; Painter, G. R.; Hosteller, K. Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003, 59, 163-171.
64. Byrd, C. M.; Bolken, T. C.; Mjalli, A. M.; Arimilli, M. N.; Andrews, R. C.; Rothlein, R.; Andrea, T.; Rao, M.; Owens, K. L.; Hruby, D. E. New class of orthopoxvirus antiviral drugs that block viral maturation. J. Virol. 2004, 78, 12147-12156.
65. Tseng, C. K. Overview of antiviral drug discovery and development. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; pp 31-82.
66. Ono, A.; Okamoto, T.; Inada, M.; Nara, H.; Matsuda, A. Nucleosides and nucleotides. 131. Synthesis and properties of oligonucleotides containing 5-formyl-2′-deoxyuridine. Chem. Pharm. Bull. (Tokyo) 1994, 42, 2231-2237.
67. Nomura, M.; Shuto, S.; Matsuda, A. Synthesis of the cyclic and acyclic acetal derivatives of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, a potent antitumor nucleoside. Design of prodrugs to be selectively activated in tumor tissues via the bio-reduction-hydrolysis mechanism. Bioorg. Med. Chem. 2003, 11, 2453-2461.
68. Mahmud, N. P.; Garrett, S. W.; Threadgill, M. D. The 5-nitrofuran-2- ylmethylidene group as a potential bioreductively activated prodrug system for diol-containing drugs. Anticancer Drug Des. 1998, 13, 655-662.
69. Park, J. S.; Chang, C. T.; Schmidt, C. L.; Colander, Y.; De Clercq, E.; Descamps, J.; Mertes, M. P. Oxime and dithiolane derivatives of 5-formyl-2′-deoxyuridine and their 5′-phosphates: antiviral effects and thymidylate synthetase inhibition. J. Med. Chem. 1980, 23, 3, 661-665.
70. Otvos, L.; Tudos, F. H. Hevizos ointment efficacy in view of molecular pharmacology. Acta Pharm. Hung. 1993, 63, 237-242.
71. Sagi, J.; Szabolcs, A.; Szemzo, A.; Michaela, V.; Jaroslav, K.; Jitka, S.; Alena, S.; Otvos, L. Incorporation of the antiherpetic 5-isopropyl-2′- deoxyuridine into a synthetic DNA and the consequence of incorporation on structure and functions of the DNA. Acta Pharm. Hung. 1993, 63, 204-214.
72. Sagi, J.; Szabolcs, A.; Szemzo, A.; Otvos, L. Modified polynucleotides. VII. Impaired integrity of a synthetic DNA containing the antiherpetic agent 5-isopropyl-2′-deoxyuridine. Nucleic Acids Res. 1986, 14, 3449-3462.
73. Verri, A.; Focher, F.; Duncombe, R. J.; Basnak, I.; Walker, R. T.; Coe, P. L.; de Clercq, E.; Andrei, G.; Snoeck, R.; Balzarini, J.; Spadari, S. Anti-(herpes simplex virus) activity of 4′-thio-2′-deoxyuridines: a biochemical investigation for viral and cellular target enzymes. Biochem. J. 2000, 351, 319-326.